Cargando…

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer

Triple-negative breast cancer (TNBC) is characterized as an aggressive form of breast cancer (BC) associated with poor patient outcomes. For the majority of patients, there is a lack of approved targeted therapies. Therefore, chemotherapy remains a key treatment option for these patients, but signif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eustace, Alex J., Lee, Min Jie, Colley, Grace, Roban, Jack, Downing, Tim, Buchanan, Paul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511797/ https://www.ncbi.nlm.nih.gov/pubmed/36176752 http://dx.doi.org/10.20517/cdr.2022.41

Ejemplares similares

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Data pertaining to aberrant intracellular calcium handling during androgen deprivation therapy in prostate cancer
por: O'Reilly, Debbie, et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
por: Feng, Xiangling, et al.
Publicado: (2022)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Anomalous altered expressions of downstream gene-targets in TP53-miRNA pathways in head and neck cancer
por: Mitra, Sanga, et al.
Publicado: (2014)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Establishing the Link between X-Chromosome Aberrations and TP53 Status, with Breast Cancer Patient Outcomes
por: Caramia, Franco, et al.
Publicado: (2023)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients
por: Manoharan, Vahinipriya, et al.
Publicado: (2020)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Long noncoding RNA–mediated activation of PROTOR1/PRR5-AKT signaling shunt downstream of PI3K in triple-negative breast cancer
por: Tu, Zhenbo, et al.
Publicado: (2022)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish
por: Luo, Juanjuan, et al.
Publicado: (2020)

Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma
por: Wan, Huiying, et al.
Publicado: (2021)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway
por: Chen, Xiaojun, et al.
Publicado: (2021)

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
por: Luo, Yanli, et al.
Publicado: (2018)

TP53 Status is Associated with Thrombospondin1 Expression In vitro
por: Alvarez Secord, Angeles, et al.
Publicado: (2013)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Spontaneous and inherited TP53 genetic alterations
por: Levine, Arnold J.
Publicado: (2021)

The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations
por: Boyle, J M, et al.
Publicado: (2001)

Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway
por: Martinez, Jarrod D., et al.
Publicado: (2022)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
por: Lorenz, Susanne, et al.
Publicado: (2015)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ps4qsep8becp005go758l48em6